Caseware UK (AP4) 2024.0.164 2024.0.164 2025-04-30 2025-04-30 false false 2024-05-01 No description of principal activity 28 28 true true The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11923594 2024-05-01 2025-04-30 11923594 2023-05-01 2024-04-30 11923594 2025-04-30 11923594 2024-04-30 11923594 c:Director3 2024-05-01 2025-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2024-05-01 2025-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2025-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2024-04-30 11923594 d:PlantMachinery 2024-05-01 2025-04-30 11923594 d:PlantMachinery 2025-04-30 11923594 d:PlantMachinery 2024-04-30 11923594 d:PlantMachinery d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 11923594 d:MotorVehicles 2024-05-01 2025-04-30 11923594 d:MotorVehicles 2025-04-30 11923594 d:MotorVehicles 2024-04-30 11923594 d:MotorVehicles d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 11923594 d:FurnitureFittings 2024-05-01 2025-04-30 11923594 d:FurnitureFittings 2025-04-30 11923594 d:FurnitureFittings 2024-04-30 11923594 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 11923594 d:ComputerEquipment 2024-05-01 2025-04-30 11923594 d:ComputerEquipment 2025-04-30 11923594 d:ComputerEquipment 2024-04-30 11923594 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 11923594 d:OwnedOrFreeholdAssets 2024-05-01 2025-04-30 11923594 d:Goodwill 2024-05-01 2025-04-30 11923594 d:Goodwill 2025-04-30 11923594 d:Goodwill 2024-04-30 11923594 d:CurrentFinancialInstruments 2025-04-30 11923594 d:CurrentFinancialInstruments 2024-04-30 11923594 d:Non-currentFinancialInstruments 2025-04-30 11923594 d:Non-currentFinancialInstruments 2024-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2025-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2025-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2024-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-04-30 11923594 d:ShareCapital 2025-04-30 11923594 d:ShareCapital 2024-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2025-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2024-04-30 11923594 c:FRS102 2024-05-01 2025-04-30 11923594 c:AuditExempt-NoAccountantsReport 2024-05-01 2025-04-30 11923594 c:FullAccounts 2024-05-01 2025-04-30 11923594 c:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 11923594 d:Goodwill d:OwnedIntangibleAssets 2024-05-01 2025-04-30 11923594 e:PoundSterling 2024-05-01 2025-04-30 iso4217:GBP xbrli:pure

Registered number: 11923594 WEELSBY VIEW PHARMACY LTD UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 30 APRIL 2025
WEELSBY VIEW PHARMACY LTD REGISTERED NUMBER: 11923594 BALANCE SHEET AS AT 30 APRIL 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Intangible assets | 4 |  | 549,085 |  | 617,719
Tangible assets | 5 |  | 297,819 |  | 293,824
|  |  | 846,904 |  | 911,543
Current assets |  |  |  |  |
Stocks | 6 | 360,084 |  | 372,294 |
Debtors: amounts falling due after more than one year | 7 | 47,711 |  | 47,711 |
Debtors: amounts falling due within one year | 7 | 548,384 |  | 460,187 |
Cash at bank and in hand | 8 | 265,146 |  | 362,260 |
|  | 1,221,325 |  | 1,242,452 |
Creditors: amounts falling due within one year | 9 | (424,304) |  | (423,635) |
Net current assets |  |  | 797,021 |  | 818,817
Total assets less current liabilities |  |  | 1,643,925 |  | 1,730,360
Creditors: amounts falling due after more than one year | 10 |  | (396,565) |  | (632,671)
Net assets |  |  | 1,247,360 |  | 1,097,689
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 100 |  | 100
Profit and loss account |  |  | 1,247,260 |  | 1,097,589
|  |  | 1,247,360 |  | 1,097,689
Page 1
WEELSBY VIEW PHARMACY LTD REGISTERED NUMBER: 11923594 BALANCE SHEET (CONTINUED) AS AT 30 APRIL 2025 The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 16 October 2025.
Dr J M Raghwani
Director
The notes on pages 3 to 10 form part of these financial statements. Page 2
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025
1. | General information
Weelsby View Pharmacy Ltd is a private company limited by shares. The company is incorporated in England & Wales and its registered office address is Aston House, Cornwall Avenue, London, N3 1LF. The registered number is 11923594. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The financial statements are presented in Sterling (£), which is the functional currency of the entity. The following principal accounting policies have been applied:
| 2.2 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the Company has transferred the significant risks and rewards of ownership to the buyer; ∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the Company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably. Page 3
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025 2.Accounting policies (continued)
| 2.3 | Taxation
Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income ot to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in United Kingdom.
| 2.4 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.5 | Borrowing costs
All borrowing costs are recognised in profit or loss in the year in which they are incurred.
| 2.6 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.
| 2.7 | Intangible assets
Goodwill Goodwill represents the difference between amounts paid on the cost of a business combination and the acquirer’s interest in the fair value of its identifiable assets and liabilities of the acquiree at the date of acquisition. Subsequent to initial recognition, goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight-line basis to the Statement of Income and Retained Earnings over its useful economic life. Other intangible assets Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years. Page 4
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025 2.Accounting policies (continued)
| 2.8 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis. Depreciation is provided on the following basis:
|  |  |  | Long-term leasehold property | - |  | Straight Line Method for 10 years
|  |  |  | Plant and machinery | - | 25% | Reducing Balance Method
|  |  |  | Motor vehicles | - | 25% | Reducing Balance Method
|  |  |  | Fixtures and fittings | - | 25% | Reducing Balance Method
|  |  |  | Computer equipment | - | 25% | Reducing Balance Method
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.9 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
| 2.10 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.11 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. Page 5
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025 2.Accounting policies (continued)
| 2.12 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Employees
| The average monthly number of employees, including directors, during the year was 28 (2024 - 28).
4. | Intangible assets
|  | Goodwill
|  | £
| Cost |
| At 1 May 2024 | 686,355
| At 30 April 2025 | 686,355
| Amortisation |
| At 1 May 2024 | 68,635
| Charge for the year on owned assets | 68,635
| At 30 April 2025 | 137,270
| Net book value |
| At 30 April 2025 | 549,085
| At 30 April 2024 | 617,719
Page 6

|  | WEELSBY VIEW PHARMACY LTD |
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025
| 5. | Tangible fixed assets
|  | Long-term leasehold property | Plant and machinery | Motor vehicles | Fixtures and fittings | Computer equipment | Total
|  | £ | £ | £ | £ | £ | £
| Cost or valuation |  |  |  |  |  |
| At 1 May 2024 | 242,989 | 157,211 | 7,079 | 59,839 | 4,797 | 471,915
| Additions | - | - | 79,834 | - | 9,030 | 88,864
| At 30 April 2025 | 242,989 | 157,211 | 86,913 | 59,839 | 13,827 | 560,779
| Depreciation |  |  |  |  |  |
| At 1 May 2024 | 91,122 | 58,845 | 3,346 | 24,286 | 493 | 178,092
| Charge for the year on owned assets | 30,374 | 24,592 | 20,892 | 6,137 | 2,873 | 84,868
| At 30 April 2025 | 121,496 | 83,437 | 24,238 | 30,423 | 3,366 | 262,960
| Net book value |  |  |  |  |  |
| At 30 April 2025 | 121,493 | 73,774 | 62,675 | 29,416 | 10,461 | 297,819
| At 30 April 2024 | 151,867 | 98,367 | 3,733 | 35,553 | 4,304 | 293,824
Page 7

WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025
6. | Stocks
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Finished goods and goods for resale | 360,084 | 372,294
|  | 360,084 | 372,294
7. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due after more than one year |  |
| Other debtors | 47,711 | 47,711
|  | 47,711 | 47,711
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Due within one year |  |
| Trade debtors | 410,386 | 323,190
| Amounts owed by group undertakings | 21,589 | 20,000
| Other debtors | 49,326 | 56,754
| Prepayments and accrued income | 67,083 | 60,243
|  | 548,384 | 460,187
8. | Cash and cash equivalents
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Cash at bank and in hand | 265,146 | 362,260
|  | 265,146 | 362,260
Page 8
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025
9. | Creditors: Amounts falling due within one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Bank loans | 124,001 | 124,001
| Trade creditors | 209,387 | 196,546
| Corporation tax | 71,272 | 80,150
| Other taxation and social security | 2,280 | 2,281
| Other creditors | 11,712 | 14,616
| Accruals and deferred income | 5,652 | 6,041
|  | 424,304 | 423,635
10. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Bank loans | 145,040 | 322,562
| Amounts owed to group undertakings | 251,525 | 310,109
|  | 396,565 | 632,671
Page 9
WEELSBY VIEW PHARMACY LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2025
11. | Loans
| Analysis of the maturity of loans is given below:
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Amounts falling due within one year |  |
| Bank loans | 124,001 | 124,001
|  | 124,001 | 124,001
| Amounts falling due 1-2 years |  |
| Bank loans | 124,001 | 124,001
|  | 124,001 | 124,001
| Amounts falling due 2-5 years |  |
| Bank loans | 21,040 | 198,561
|  | 21,040 | 198,561
|  | 269,042 | 446,563
Page 10